Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YXZQL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-15
|
|||||
| Synonyms |
BMS-182248; BMS-182248-01; BR96-DAPDOX; BR96-DOX; CBR96-Doxorubicin Immunoconjugate; SGN 15; SGN-15; SGN15; hBR96
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Phase 2 (Terminated)
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-Lewis-Y mAb cBR96
|
Antibody Info | ||||
| Antigen Name |
Lewis Y
|
Antigen Info | ||||
| Payload Name |
Doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Acid-labile linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
